These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30854694)

  • 1. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
    Corey KE; Wilson LA; Altinbas A; Yates KP; Kleiner DE; Chung RT; Krauss RM; Chalasani N;
    Aliment Pharmacol Ther; 2019 May; 49(9):1205-1213. PubMed ID: 30854694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
    Corey KE; Vuppalanchi R; Wilson LA; Cummings OW; Chalasani N;
    Aliment Pharmacol Ther; 2015 Feb; 41(3):301-9. PubMed ID: 25429853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.
    Gurka MJ; Mack JA; Chi X; DeBoer MD
    J Gastroenterol Hepatol; 2021 Jan; 36(1):249-256. PubMed ID: 32506513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
    Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
    Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.
    Corey KE; Vuppalanchi R; Vos M; Kohli R; Molleston JP; Wilson L; Unalp-Arida A; Cummings OW; Lavine JE; Chalasani N;
    J Pediatr Gastroenterol Nutr; 2015 Mar; 60(3):360-7. PubMed ID: 25714579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis.
    Castillo-Leon E; Connelly MA; Konomi JV; Caltharp S; Cleeton R; Vos MB
    Pediatr Obes; 2020 Sep; 15(9):e12648. PubMed ID: 32367624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile.
    Corey KE; Misdraji J; Gelrud L; Zheng H; Chung RT; Krauss RM
    Lipids Health Dis; 2014 Jun; 13():100. PubMed ID: 24952382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease.
    Yates KP; Deppe R; Comerford M; Masuoka H; Cummings OW; Tonascia J; Chalasani N; Vuppalanchi R;
    PLoS One; 2017; 12(11):e0185813. PubMed ID: 29095942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
    Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
    Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease.
    Ustyol A; Aycan Ustyol E; Gurdol F; Kokali F; Bekpınar S
    Scand J Clin Lab Invest; 2017 May; 77(3):205-209. PubMed ID: 28318371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
    J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
    Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
    Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
    Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
    J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E and nonalcoholic fatty liver disease.
    Pacana T; Sanyal AJ
    Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials.
    Athinarayanan S; Wei R; Zhang M; Bai S; Traber MG; Yates K; Cummings OW; Molleston J; Liu W; Chalasani N
    PLoS One; 2014; 9(4):e95366. PubMed ID: 24759732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia.
    Turhan H; Erbay AR; Yasar AS; Aksoy Y; Bicer A; Yetkin G; Yetkin E
    Coron Artery Dis; 2005 Feb; 16(1):45-50. PubMed ID: 15654200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.